Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.64 |
| ▸ | KDM5B | Q9UGL1 | 7/20 | 0.64 |
| ▸ | KDM2B | Q8NHM5 | 5/20 | 0.64 |
| ▸ | PHF8 | Q9UPP1 | 6/20 | 0.53 |
| ▸ | KDM5A | P29375 | 3/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16034201 | 0.84 | KDM5B (0.61) | KDM4CKDM5BKDM2BPHF8KDM5A | |
| SCHEMBL16033942 | 0.79 | KDM4C (1.00) | KDM4CKDM5BKDM2BPHF8KDM5A | |
| SCHEMBL20979023 | 0.78 | KDM4C (0.57) | KDM4CKDM5BKDM2BPHF8KDM5A | |
| SCHEMBL17891761 | 0.78 | KDM5B (0.70) | KDM4CKDM5BKDM2BPHF8KDM5A | |
| SCHEMBL19383331 | 0.78 | KDM4C (0.57) | KDM4CKDM5BKDM2BPHF8KDM5A | |
| SCHEMBL17898929 | 0.77 | KDM5B (0.69) | KDM4CKDM5BKDM2BPHF8KDM5A | |
| SCHEMBL16033687 | 0.73 | KDM4C (0.61) | KDM4CKDM5BKDM2BPHF8KDM5A | |
| SCHEMBL17604518 | 0.70 | PHF8 (0.73) | KDM4CKDM5BKDM2BPHF8KDM5A | |
| SCHEMBL17706047 | 0.70 | KDM4C (0.47) | KDM4CKDM5BKDM2BPHF8KDM5A | |
| SCHEMBL17695473 | 0.69 | PHF8 (0.67) | KDM4CKDM5BKDM2BPHF8KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133166-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133166-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 13/4885KDM5B 10/4885KDM2B 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.